aclarubicin 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
antineoplastics, daunorubicin derivatives 80 57576-44-0

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • aclacinomycin
  • Aclacinomycin A
  • aclacur
  • aclarubicin
  • Antibiotic 3082A
  • aclarubicin hydrochloride
  • aclarubicin HCl
An anthracycline produced by Streptomyces galilaeus. It has potent antineoplastic activity.Aclarubicin is evaluated for the treatment of different conditions like acute myeloid leukemia, thyroid cancer, gastric cancer, lymphoma, small cell lung cancer. It is an inhibitor of topoisomerase II inhibitor being used in combination with different anticancerous drugs to obtain best therapeutic results and to reduce toxicity or side effects.
  • Molecular weight: 811.88
  • Formula: C42H53NO15
  • CLOGP: 3.37
  • LIPINSKI: 2
  • HAC: 16
  • HDO: 4
  • TPSA: 217.05
  • ALOGS: -3.57
  • ROTB: 10

Drug dosage:

None

ADMET properties:

None

Approvals:

None

FDA Adverse Event Reporting System (Female)

FDA Adverse Event Reporting System (Male)

FDA Adverse Event Reporting System (Geriatric)

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Drug Use | Suggest Off label Use Form| |View source of the data|




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

External reference:

Pharmaceutical products:

None

aclarubicin